Researchers say patient survival is only slightly affected when physicians decide to switch to a second-line series of HIV/AIDS drugs based on clinical symptoms rather than expensive lab tests.
Published in Brief:
|Sr. Business Systems Analyst||
|Staff VP Medical Policy Development-81321||
|Sr. Report Developer Medical Claims||
Geisinger Health System
|Chief Medical Officer||
New Century Health